Welcome to our dedicated page for Niagen Bioscience SEC filings (Ticker: NAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Niagen Bioscience, Inc. (NASDAQ: NAGE) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a structured view into how this NAD+ and healthy-aging focused bioscience business reports its operations, strategy, and governance. These documents complement the company’s press releases by providing formal detail on financial results, material agreements, equity plans, and other regulatory matters.
For investors tracking NAGE, periodic reports such as Forms 10-K and 10-Q (when available) are central references for understanding revenue drivers like Tru Niagen® consumer supplements, Niagen® ingredient sales, and pharmaceutical-grade Niagen Plus™ IV and injectable products. They also typically describe research and development priorities, intellectual property portfolios around nicotinamide riboside and other NAD+ precursors, and risk factors relevant to the company’s position in the biotechnology and dietary supplement markets.
Current reports on Form 8-K, several of which are summarized in the recent record, document specific events such as quarterly earnings announcements, share repurchase program authorizations, changes to financial outlook, material supply agreements for nicotinamide-beta-riboside chloride, and patent assignment transactions with Queen’s University Belfast. Other filings detail stockholder approvals of equity incentive plan amendments and employee stock purchase plans, which shape dilution and compensation structures.
On Stock Titan, these filings are paired with AI-powered summaries that help explain complex sections, from revenue and margin discussions to the implications of IP and supply agreements. Users can quickly scan key points in 10-K and 10-Q reports, review 8-K event disclosures, and access information relevant to insider and equity activity through forms such as Form 4 when available. Real-time updates from EDGAR ensure that new Niagen Bioscience filings appear promptly, while AI-generated highlights make it easier to interpret how each document fits into the company’s broader NAD+ science and healthy-aging strategy.
Niagen Bioscience, Inc. announced that its Board of Directors has doubled the company’s share repurchase authorization to $20 million of outstanding common stock, up from the previously approved $10 million program.
Through March 17, 2026, Niagen Bioscience has repurchased approximately $2.6 million of its common stock under this program. The repurchase authorization runs through October 31, 2027, unless earlier completed, suspended, modified, or terminated by the Board. Repurchases may occur from time to time via open market purchases, privately negotiated transactions, or trading plans, and the company is not obligated to repurchase any specific amount.
Niagen Bioscience, Inc. reported strong growth for 2025, with net sales rising 30% to $129.4 million and gross margin improving 250 basis points to 64.3%. Net income more than doubled to $17.4 million, or $0.22 basic EPS, and Adjusted EBITDA increased to $20.4 million.
The company ended 2025 with $64.8 million in cash and no outstanding borrowings, supported by $13.5 million of operating cash flow. Tru Niagen and Niagen ingredient sales grew 27% and 45%, respectively, and 2026 guidance calls for 10–15% net sales growth and slightly higher margins as it invests in marketing, R&D, and infrastructure.
Niagen Bioscience, Inc. is a Delaware-based bioscience company focused on healthy aging through nicotinamide adenine dinucleotide (NAD+) science. It sells Tru Niagen dietary supplements and Niagen ingredients globally, and is developing pharmaceutical applications that have not yet generated revenue.
Net sales grew to approximately $129.4 million in 2025 from $99.6 million in 2024, a 30% increase and an 18% compound annual growth rate from 2021 to 2025. Growth was led by the consumer products segment at $97.7 million and ingredients at $28.7 million. No customer represented more than 10% of 2025 sales.
The company strengthened its balance sheet, ending 2025 with about $64.8 million in cash and net working capital of $19.4 million, and has an undrawn $10 million credit line. In February 2026 it agreed to sell its analytical reference standards and services segment to concentrate on core NAD+ consumer, ingredient, and pharmaceutical opportunities, supported by an extensive patent portfolio and over 300 research collaborations.
Niagen Bioscience, Inc. is reshaping its business by selling substantially all assets of its analytical reference standards and services unit, operated through ChromaDex, Inc. and ChromaDex Analytics, Inc., to VHG Labs, part of LGC Group, in an all-cash transaction that closed on February 24, 2026. The divestiture is described as part of a broader strategy to exit non-core activities so the company can concentrate on its NAD+ science platform, intellectual property, and commercial growth initiatives in healthy aging and longevity. Niagen will also provide certain operational and administrative transition services to the buyer for up to six months after closing in exchange for service fees recognized as the services are performed.
Lopez Carlos Luis reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that its SVP and General Counsel, Carlos Luis Lopez, received a grant of employee stock options covering 41,420 shares on the reported grant date. The options were awarded at no purchase price on grant and will vest in four equal annual installments on each anniversary of the grant date.
Pamir Ozan reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that its Chief Financial Officer, Pamir Ozan, received a grant of employee stock options covering 62,131 shares of common stock. The options were awarded at no cost as part of his compensation.
According to the vesting terms, one-fourth of the options will vest on each anniversary of the grant date, spreading the potential ownership benefits over four years and tying them to continued service with the company.
Fried Robert N reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that Chief Executive Officer Robert N. Fried received a grant of employee stock options covering 503,937 shares on the reported date. The options were granted at no cash cost to him and are held directly. One-fourth of the options vest on each anniversary of the grant date, spreading vesting over four years.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership in Niagen Bioscience Inc.
The firm reports beneficial ownership of 3,286,498 shares of Niagen Bioscience common stock, representing 4.11% of the class. It has shared voting power over 446,427 shares and shared dispositive power over 3,286,498 shares, with no sole voting or dispositive power.
The filing notes that Vanguard’s clients have the right to receive dividends and sale proceeds from these securities, and that no single client holds more than 5% of the class. Vanguard states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Niagen Bioscience.
The document also explains that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately on a disaggregated basis while pursuing the same investment strategies as before the realignment.
Niagen Bioscience, Inc. reported that its subsidiary ChromaDex, Inc. entered into a new assignment agreement with Queen’s University Belfast, effective December 16, 2025, replacing prior joint ownership and license arrangements. QUB assigned all of its rights in certain patent assets to ChromaDex and released the company from royalty, payment, accounting, and related obligations under the former agreements, including royalties accrued through 2025. In return, ChromaDex will make a one-time payment of approximately $1,000,000 for accrued royalties through 2024, annual payments of $500,000 and £35,000 from 2026 to 2038, and additional one-time payments of $1,500,000 in 2035 and $2,000,000 in 2038. The agreement includes customary representations, warranties, and indemnities, and the company disclosed that it issued a related press release.
Niagen Bioscience, Inc. (NAGE) reported insider share purchases by its Chief Financial Officer on a Form 4. On 11/14/2025, the CFO bought 4,464.962 shares of common stock in a direct transaction at a weighted average price of $6.81, with individual trade prices ranging from $6.7975 to $6.82. After this transaction, the CFO directly owned 7,372.159 shares of Niagen Bioscience common stock. On the same date, the CFO’s spouse acquired 2,220.443 shares at $6.85, which are reported as indirectly owned, bringing the indirect beneficial ownership to 2,220.443 shares.